Open AccessDalbavancin: a novel antimicrobial
Author(s) -
Chen A. Y.,
Zervos M. J.,
Vazquez J. A.
Publication year - 2007
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/j.1742-1241.2007.01318.x
Subject(s) - dalbavancin , medicine , linezolid , antimicrobial , antibiotics , safety profile , adverse effect , microbiology and biotechnology , vancomycin , staphylococcus aureus , bacteria , biology , genetics
Summary The increasing incidence of serious infections because of Gram‐positive pathogens and the rising cost in parenteral administration of antimicrobials has inspired the development of a novel antibiotic. Dalbavancin is the first once a week antibiotic with activity against a broad range of Gram‐positive pathogens. A large multicentre, pivotal, Phase III clinical trial, which included 854 patients with complicated skin and skin structure infections, compared 1–2 doses of dalbavancin vs. linezolid. The results demonstrated non‐inferiority and a comparable safety profile. With its unique pharmacokinetic profile, ease of use and excellent safety profile, dalbavancin should provide a valuable addition to the armamentarium used to treat infections because of Gram‐positive cocci.